

Mossberg's Investor Digest

July 2009

Issue #13

From the Editor...

For those Nasdaq-listed companies that are trading below \$1 per share, Nasdaq gave them a few more weeks (August 3) to get their stock prices above \$1, or face de-listing. This latest reprieve is the third time the suspension of the minimum \$1 bid price rule has been extended, since it was put in place on October 16, 2008. Nasdaq said that based on discussions with the SEC, it does not expect a further extension.

I ran a quick screen of Nasdaq companies trading below \$1, which yielded 253 companies, or about 7% of the 3,800 Nasdaq-listed companies. By way of comparison, there were 64 Nasdaq-listed companies below \$1 on September 30, 2007, and 344 on October 9, 2008.

The rule states that if the closing bid price falls below \$1 for 30 consecutive business days, the company has six months to resolve the problem or face de-listing. Companies face three alternatives to remedy the situation. **1) Reverse stock split** – This is likely the most attractive option for many companies. For example, a company could exchange 1 share of stock for each 10 shares of stock outstanding, effectively decreasing the amount of shares outstanding and increasing the share price by a factor of 10. (Instead of owning 100 shares of stock at \$0.50, a stockholder would own 10 shares at \$5.00 each.) **2) Proactive investor marketing** – For those companies whose share prices may be 10% to 20% below the \$1 mark and have decent near-term prospects for improved financial performance, a little promotion might help lift shares above the minimum level. **3) De-listing** – Given the current market conditions, some companies may choose to let their stock be de-listed. While this alternative will save the company listing fees, it's not a very attractive solution. Companies that choose this route may face forced selling by investors who are unable (by charter)/ unwilling to own non-listed securities, and will face more difficult standards to re-list on the exchange as economic conditions improve. For example, the current minimum bid price for initial listing on the Nasdaq is \$4.

Thank you for your interest in Mossberg's Investor Digest. I welcome your feedback.

Dave Mossberg

July 2009 Issue

Mattel (NYSE: MAT) - \$15.19, July 13, 2009, Page 3 – With efficiencies of scale, leading market share and brand power, Mattel has a great business that requires limited capital investment and has produced return on equity in the high teens to mid 20s since 2001. Trading at just 7.8x EV/ EBITDA, this appears to be a bargain price. While it is unlikely that the valuation multiple will expand much in the near term due to expected weakness in top line performance, profitability should actually grow this year due to cost cutting initiatives. Its competitive position should allow Mattel to grow faster than its peers coming out of the bottom of the cycle. The dividend appears to be in good shape, so you can collect a nice 4.9% yield while you wait.

Novavax (Nasdaq: NVAX) - \$3.04, July 20, 2009, Page 4 – It appears that NVAX has a unique solution and capable people that can make the company a significant player in the market for vaccines (the seasonal flu vaccine market alone is expected to be a \$6 billion market in 4 years). If proven efficacious, the company's VLP may change not only flu vaccine production, but the way all vaccines are produced. This would make Novavax a very valuable property, indeed.

ABB Ltd. (NYSE: ABB) – \$16.30, July 20, 2009, Page 5 – ABB's financial performance is likely to be affected in the near term by the downturn in the economic cycle. However, the valuation of 6.3x EV/EBITDA for a company that has delivered average returns in excess of 30% for the past 4 years appears very attractive. In addition, the secular trend of world wide investments in "Smart Grids" could provide growth opportunities for years to come. While shares may trade sideways until the economy recovers, the dividend offers an attractive yield of nearly 3% for patient long-term investors.

Teva (Nasdaq: TEVA) – \$49.39, July 21, 2009, Page 6 – During a bright time for the generic drug industry, Teva, the largest generic drug company in the world, is trading at an attractive multiple of just 15x 2009 EPS. Given the company's 30%+ EPS growth rate and long term visibility, these shares could command a higher EPS multiple near 18-20x.

We attempt to provide subscribers with reasoned opinions based on our analysis of publicly available information from sources believed to be reliable, but make no representations as to its accuracy or completeness. Best Idea profiles are not based upon individual needs of subscribers nor are they an offer to buy or sell securities. Additional disclosures can be found under the Disclosures portion of the Mossberg's Investor Digest website.

www.mossbergid.com

Mossberg's Investor Digest

Mossberg's Investor Digest Idea Performance

This month marks the first full year of Mossberg's Investor Digest, so I thought I'd let readers know how the ideas have performed. Since July of 2008, there have been 56 ideas published in the letter. On average the ideas are up 16%, 13 percentage points better than the market. Over two thirds, or 9 out of the 13 issues, have outperformed.

Since the beginning of the year, performance has been even better. Below is a table with the performance of the ideas compared to the broad market Russell 3000 Index. The thesis of the newsletter is that the best ideas of the smartest investors I know should outperform the market. So far...so good.

Ticker	Pub Date	Original Price	Current Price	Change	Russell 3000 Change Since Pub Date	Relative Perf
ITWO	9-Jan	6.49	13.32	105.2%	8.6%	96.7%
CRN	23-Jan	14.67	17.63	20.2%	19.1%	1.1%
CFL	28-Jan	22.46	29.11	29.6%	13.2%	16.4%
SPRO	29-Jan	2.65	4.17	57.4%	17.2%	40.2%
DSX	17-Feb	13.81	14.95	8.3%	25.0%	-16.8%
DGIT	20-Feb	15.84	20.66	30.4%	28.4%	2.0%
SVVS	25-Feb	5.79	13.31	129.9%	29.4%	100.4%
ANIK	28-Feb	3.42	5.75	68.1%	34.4%	33.7%
WRLD	13-Mar	14.08	25.19	78.9%	30.8%	48.1%
ISSI	20-Mar	1.55	2.94	89.7%	28.8%	60.9%
IVAC	23-Mar	5.34	10.13	89.7%	21.2%	68.5%
CSV	30-Mar	1.50	3.36	124.0%	25.5%	98.5%
PUR	14-Apr	3.26	4.00	22.7%	17.1%	5.6%
RSH	20-Apr	9.68	16.06	65.9%	18.2%	47.7%
EPM	24-Apr	2.68	2.78	3.7%	13.3%	-9.6%
PLUS	29-Apr	12.00	15.22	26.8%	12.1%	14.7%
SIG	11-May	17.76	21.54	21.3%	7.9%	13.4%
SMBL	15-May	7.71	6.06	-21.4%	11.5%	-32.9%
VRTS	22-May	15.15	15.85	4.6%	10.8%	-6.2%
CHCG.OB	31-May	1.08	0.86	-20.4%	6.8%	-27.2%
VRTU	16-Jun	7.26	9.43	29.9%	7.7%	22.2%
MEDQ	18-Jun	5.17	7.19	39.1%	6.8%	32.2%
GME	26-Jun	22.17	23.45	5.8%	6.6%	-0.9%
CPY	29-Jun	16.62	17.90	7.7%	5.8%	1.9%
MAT	10-Jul	15.19	17.32	14.0%	11.3%	2.7%
NVAX	17-Jul	3.04	4.21	38.5%	4.3%	34.2%
ABB	20-Jul	16.30	17.61	8.0%	4.3%	3.8%
TEVA	21-Jul	49.39	51.12	3.5%	3.0%	0.5%
Average				38.6%	15.3%	23.3%

The table above shows the relative increase (decrease) in the value of the ideas published during the past seven months. For comparison purposes, the relative change in the Russell 3000 Index is shown. **Performance data quoted represents past performance and does not guarantee future results.** Current performance of the ideas may be lower or higher than the performance quoted. Investors should consult a financial advisor before investing in any securities highlighted in the Digest or subscribing to any newsletter service. Best Idea profiles highlighted in Mossberg's Investor Digest are not based upon individual needs of subscribers nor are they an offer to buy or sell securities.

We attempt to provide subscribers with reasoned opinions based on our analysis of publicly available information from sources believed to be reliable, but make no representations as to its accuracy or completeness. Best Idea profiles are not based upon individual needs of subscribers nor are they an offer to buy or sell securities. Additional disclosures can be found under the Disclosures portion of the Mossberg's Investor Digest website.

Mossberg's Investor Digest

Best Idea Profile

Mattel (NYSE: MAT)

DESCRIPTION:

Headquartered in El Segundo, CA; Mattel is the largest toy company in the world with approximately 20% of the U.S. toy market. It's toy brands include Fisher Price, Barbie, Matchbox, and Hotwheels (among others) with 80%+ of its product portfolio geared to young children from birth to 9 years old. The company generates approximately 50% of its sales outside of the United States.

KEY INVESTMENT CONSIDERATIONS:

Toy sales tend to outperform other categories during a recession – During 4Q08, toy sales declined 5%, versus 5% decline in electronics, 7% decline in apparel, 13% decline in furniture and 24% decline in automobiles. While Mattel and the rest of the toy industry will surely face a weak consumer this peak selling season, parents are more likely to cut back on their own purchases than deny their children new toys at during the holidays.

The big toy companies will take share from the smaller ones – The toy market is fragmented with the top 8 players commanding only 56% of the toy market. In the current economic environment, the largest toy companies will take share from the smaller ones. With less brand and pricing power, smaller toy companies are struggling. Anecdotally, KB toys recently filed for Chapter 11, closing 600 of its 1,200 stores. The loss of a significant customer can be devastating for smaller, less diverse toy companies. In addition, nearly 1,000 toy exporters shut their doors in southern China last year. All this means less competition for Mattel.

Competitive moat increases pricing power – According to The NPD Group, Mattel had 21% of the U.S. toy market. This compares to 35% for the next 7 largest companies combined. Its size and brand power allow Mattel to have more control over pricing when compared to other, smaller toy companies. According to NPD, Mattel's price points increased 8.5% during 2008 and the company has recently implemented another round of price increases.

- **Branding** – At 50 years old, Barbie is the most popular doll in the world.
- **Less dependent on big three toy retailers** – Wal-Mart, Toys "R" Us, and Target control about 2/3 of the U.S. retail toy market. These are big players with significant power to drive pricing from toy vendors. However, only 38% of MAT's sales come from these three vendors, significantly less than the other toy vendors.

Longer-term favorable macro trends – Recent U.S. birth rates were the highest they have been in four decades. Mattel may be the best positioned toy company to capitalize on this trend due to its focus on young children.

Bottom line should grow much faster than the top - During 2009 and 2010 the company is putting in place costs savings initiatives designed to provide sustainable cost savings of \$180 million to \$200 million per year. To put this into perspective, that is 3 to 3 ½ percentage points of margin improvement at current sales levels.

VALUATION:

With efficiencies of scale, leading market share and brand power, Mattel has a great business that requires limited capital investment (with the exception of working capital) and has produced return on equity in the high teens to mid 20' since 2001. Trading at just 7.8x EV/ EBITDA, this appears to be a bargain price. While it is unlikely that the valuation multiple will expand much in the near term due to expected weakness in top line performance, profitability should actually grow this year due to cost cutting initiatives. Its competitive position should allow Mattel to grow faster than its peers coming out of the bottom of the cycle. The dividend appears to be in good shape, so you can collect a nice 4.9% yield while you wait.

(NYSE: MAT)

Investment Data (as of 7/10/09)

Recent Price	\$15.19
52-Week Range	10.36 - 21.95
Fiscal Year End	December
Dividend	\$0.75
Yield	4.9%
Shares Outstanding	358 MM
Average Trading Volume (3 mos)	3 MM
Market Capitalization	5.5 B
Cash	400 MM
Long Term Debt	900 MM
Enterprise Value (EV)	6.0 B
LT Debt/ Equity	0.4
BV/ Share	2.97
TTM Revenue	5.8 B
P/ Revenue	0.9x
TTM EPS (non-GAAP)	1.03
P/ EPS	14.7x
TTM EBITDA	767 MM
EV/ TTM EBITDA	7.8x

We attempt to provide subscribers with reasoned opinions based on our analysis of publicly available information from sources believed to be reliable, but make no representations as to its accuracy or completeness. Best Idea profiles are not based upon individual needs of subscribers nor are they an offer to buy or sell securities. Additional disclosures can be found under the Disclosures portion of the Mossberg's Investor Digest website.

Mossberg's Investor Digest

Best Idea Profile

Novavax, Inc. (Nasdaq: NVAX)

DESCRIPTION:

Headquartered in Rockville, MD, Novavax is a clinical-stage (they don't have meaningful revenue or earnings yet) biopharmaceutical company that focuses on making vaccines for seasonal flu, pandemic viruses (such as swine flu, avian flu), and other infectious diseases. The company's two key technologies are 1) virus-like particle (VLP) which is more effective, reduces cost and speeds development of new vaccines, and 2) disposable manufacturing technology, which can be set up quickly and requires less capital investment than traditional manufacturing, both of which are of particular interest in developing nations.

KEY INVESTMENT CONSIDERATIONS:

What is VLP and why is it better?

- **In theory, there is no way you can get infected by a VLP vaccine** – Traditional vaccines introduce a weakened or dead virus into the body, which stimulates the body to create antibodies and a memory record of the virus resulting in immunity. Sometimes the virus isn't weak enough and can only be used in relatively healthy people (5 to 49). As its name implies, the virus-like particle is not a dead or weakened virus...it's a particle that is coated with the same proteins that are on the outside of the virus. These proteins are what actually stimulate the body's immune response. Because there is no risk of viral infection, NVAX vaccines could be applicable for pediatric and elderly populations. (Clinical testing in the elderly will begin this fall.)
- **Very short development times** – Novavax can produce a new vaccine in 10 to 12 weeks versus 6 months using conventional technology.
- **Forms a stronger immune response** - Because they more closely match an individual viral strain, VLPs can trigger a more robust immune response.
- **VLPs do not need an adjuvant** - In order to be effective, traditional vaccines use an adjuvant, which acts like a booster for the vaccine and stimulates the body's immune response. Adjuvant can cause adverse reactions in patients and has been linked to autism, Gulf War Syndrome, etc.

Licensing deals with India & Spain validate the technology – NVAX has made licensing deals in Spain and India to develop seasonal and pandemic flu vaccines. The Spanish government and Rovi (the Spanish licensee) will invest \$84 million to complete clinical testing for EU approval. In India, NVAX's partner Cadila will invest \$8 million over three years to complete clinical testing for Indian approval. Both Cadila and Rovi have invested in Novavax.

Little stock with BIG players – For a company with a market cap of \$240 million, NVAX has a long line of proven leaders, including...

Rahul Singhvi (CEO) – Joined the company in 2005...previously headed vaccine manufacturing operations at Merck.

Penny Heaton (Chief Medical Officer) – Joined the company in 2006...previously head of Virology at Merck.

Thomas Monath, Kleiner Perkins (Board Member) – One of the most respected VC firms involved with pandemic issues has a board seat and owns approximately 3.5 % of the company.

The 2nd phase II testing milestone could be a near term catalyst – Results of the 2nd human study are expected to be available during the third quarter of this year and phase II testing is expected to be completed by the end of 2009. Successful data from each of the next milestones could be catalysts for the stock.

VALUATION:

With no revenue or earnings expected in the near term, valuing a biopharmaceutical company, such as NVAX is definitely challenging. It appears that NVAX has a unique solution and capable people that can make the company a significant player in the market for vaccines (the seasonal flu vaccine market alone is expected to be a \$6 billion market in 4 years). If proven efficacious, VLP may change not only flu vaccine production, but the way all vaccines are produced. This would make Novavax a very valuable property, indeed.

(Nasdaq: NVAX)

Investment Data (as of 7/17/09)

Recent Price	\$3.04
52-Week Range	0.52 - 3.88
Fiscal Year End	December
Shares Outstanding	87 MM
Average Trading Volume (3 mos)	5.6 MM
Market Capitalization	236 MM
Cash	26 MM
Long Term Debt	N/A
Enterprise Value (EV)	210 MM
LT Debt/ Equity	N/A
BV/ Share	0.54
TTM Revenue	<1 MM
TTM EPS (non-GAAP)	-0.52
TTM EBITDA	-34 MM

We attempt to provide subscribers with reasoned opinions based on our analysis of publicly available information from sources believed to be reliable, but make no representations as to its accuracy or completeness. Best Idea profiles are not based upon individual needs of subscribers nor are they an offer to buy or sell securities. Additional disclosures can be found under the Disclosures portion of the Mossberg's Investor Digest website.

Mossberg's Investor Digest

Best Idea Profile

ABB, Ltd. (NYSE: ABB)

DESCRIPTION:

Based in Switzerland, ABB provides green power and automation technology solutions for utility and industrial customers. The company has operations in 100 countries and a workforce of approximately 120,000 employees. The company has five divisions, 1) Power Products (31% of revenue) – manufactures components to transmit and distribute electricity...transformers, switchgear, circuit breakers, cables, etc. 2) Power Systems (18% of revenue) – offers turnkey systems and services for power transmission and distribution grids for power plants. 3) Automation Products (27% of revenue) - includes drives, motors and generators, low voltage products, instrumentation and analytical, and power electronics. 4) Process Automation (20% of revenue) – provides integrated solutions for control, plant optimization, and industry-specific application knowledge, and 5) Robotics (4% of revenue) – Provides industrial robots.

KEY INVESTMENT CONSIDERATIONS:

ABB is well position to be a major participant in deployment of the "Smart Grid". According to the CEO of GE, the Smart Grid will be one of the biggest investments in the first half of the 21st century. Emerging economies have to build electric grids in order to establish and grow their economies. Developed countries have to re-develop their aging infrastructure that is using technology that hasn't changed much since the days of Edison. The Smart Grid will add intelligence to the simple network that currently operates with a few lines of power headed in one direction. According to the American Society of Civil Engineers, \$2 trillion will need to be investing in the U.S. infrastructure by 2030. In addition to increasing the reliability and efficiency of the grid, these investments will need to be made in order to integrate electricity generated from renewable energy sources, smart meters, and even charging electric vehicles.

Significant investment in emerging markets lowers costs and creates partnership with emerging market governments – Over the past two years, ABB has invested \$700 million in manufacturing capacity in emerging market countries (\$350 million in China and India). Combined with other cost savings initiatives, these investments in lower cost areas will allow the company to take out \$2 billion in annual costs.

Leading supplier of renewable components (generators, inverters, etc.) for wind and solar – ABB is the largest supplier in the world of components used in the wind power industry. China alone has plans to put in 120 GW of wind power by 2020.

One of the strongest balance sheets among major players – ABB has a strong balance sheet with \$7 billion in cash and only \$2 billion in long term debt. In contrast GE has \$46 billion in cash and a half trillion in long term debt....Siemens has \$10 billion in cash and \$20 billion in long term debt.

VALUATION:

ABB's financial performance is likely to be affected in the near term by the downturn in the economic cycle. However, the valuation of 6.3x EV/EBITDA for a company that has delivered average returns in excess of 30% for the past 4 years appears very attractive. In addition, the secular trend of world wide investments in Smart Grids could provide growth opportunities for years to come. While shares may trade sideways until the economy recovers, the dividend offers an attractive yield of nearly 3% for patient long-term investors.

(NYSE: ABB)

Investment Data (as of 7/17/09)

Recent Price	\$16.30
52-Week Range	9.11 - 28.74
Fiscal Year End	December
Dividend	\$0.46
Yield	2.8%
Shares Outstanding	2.3 B
Average Trading Volume (3 mos)	4.4 MM
Market Capitalization	37 B
Cash	7.1 B
Long Term Debt	2.3 B
Enterprise Value (EV)	33 B
LT Debt/ Equity	0.2
BV/ Share	4.97
TTM Revenue	34 B
P/ Revenue	1.1x
TTM EPS (non-GAAP)	1.21
P/ EPS	13.5x
TTM EBITDA	5.2 B
EV/ TTM EBITDA	6.3x

We attempt to provide subscribers with reasoned opinions based on our analysis of publicly available information from sources believed to be reliable, but make no representations as to its accuracy or completeness. Best Idea profiles are not based upon individual needs of subscribers nor are they an offer to buy or sell securities. Additional disclosures can be found under the Disclosures portion of the Mossberg's Investor Digest website.

Mossberg's Investor Digest

Best Idea Profile

Teva Pharmaceutical industries, Ltd. (Nasdaq: TEVA)

DESCRIPTION:

Israel-based Teva is the largest generic drug company in the world. Approximately 75% of the company's drugs are generic and 25% are proprietary. The company's proprietary drugs are primarily used in the treatment of neurological, respiratory and women's health issues. The company operates in 60 countries and has 36,300 employees.

KEY INVESTMENT CONSIDERATIONS:

Strong Visibility – Teva is one of the few companies in this uncertain economy with strong visibility and confidence in future performance to give earnings guidance, not just for 2009, but for 2010 as well. Management has given EPS guidance of 3.20 to \$3.40 for 2009 and 30-35% growth in EPS for 2010.

Bright time for the generic industry

- **Favorable economic conditions** – Countries worldwide are seeking to limit the rise in drug spending. Increased use of generic drugs offers a compelling solution. According to the Generic Pharmaceutical Association, 70% of U.S. prescriptions were filled with generics, saving the system \$181 billion.
- **Favorable administration** – Healthcare reform will increase the size of the pie by including more people. The more people with insurance, the more generic drugs will be prescribed.
- **Secular growth to come from \$288 billion in patent expirations** – As drug patents expire they become available for companies, like Teva, to produce and market under generic names. From 2007 to 2015, patents will expire on drugs that generate \$288 billion in annual revenue. As of April 27, Teva had filed for approval with the FDA for 197 generic versions of drugs with expiring patents.

Proposed legislation may enact a new regulatory pathway for generic equivalents for biological drugs – In comparison to non-biologic prescription drugs, biologics lack a clear regulatory pathway through which generic equivalents can be considered for approval. With newly proposed legislation, that could be changing soon and open up a sizable new market for generic drug companies like Teva. There are plenty of reasons to open up this market to generics...the U.S. Congressional Budget Office estimates that biogenerics could save the U.S. government, including Medicare and Medicaid, \$12 billion over 10 years.

Efficiencies of scale – At the end of 2008, Teva completed the acquisition of the 5th largest generic drug company Barr. Including Barr, Teva has 24% market share and is larger than the next closest generic company by at least a factor of 2x. The company's efficiencies of scale give it significant competitive advantage when competing against other small and less cost efficient generic providers.

RISK:

The prescription drug lobby is one of the most powerful in Washington and will be fighting to keep patent rights as long as possible. While the Obama administration is a big supporter of generic drugs, if the drug lobby is successful at obstructing generic drug launches, it may negatively impact Teva's results.

VALUATION:

Shares are currently trading near their 52 week high and 15x 2009 EPS estimates. Given the company's 30%+ EPS growth rate and long term visibility, these shares could command a higher EPS multiple near 18-20x.

(Nasdaq: TEVA)

Investment Data (as of 7/20/09)

Recent Price	\$49.39
52-Week Range	35.89 - 50.35
Fiscal Year End	December
Dividend	\$0.58
Yield	1.2%
Shares Outstanding	853 MM
Average Trading Volume (3 mos)	5.3 MM
Market Capitalization	42 B
Cash	2.4 B
Long Term Debt	7.5 B
Enterprise Value (EV)	48 B
LT Debt/ Equity	0.5
BV/ Share	18.85
TTM Revenue	12 B
P/ Revenue	3.5x
2009 EPS (estimate)	3.30
P/ EPS	15.0x
TTM EBITDA	3.3 B
EV/ TTM EBITDA	14.5x

We attempt to provide subscribers with reasoned opinions based on our analysis of publicly available information from sources believed to be reliable, but make no representations as to its accuracy or completeness. Best Idea profiles are not based upon individual needs of subscribers nor are they an offer to buy or sell securities. Additional disclosures can be found under the Disclosures portion of the Mossberg's Investor Digest website.

Mossberg's Investor Digest

Subscription Information

Subscribe to Mossberg's Investor Digest at www.mossbergid.com/subscribe.html

Immediate Access Annual Subscription: \$245/ year

12 Monthly Compilation Issues – At the end of each month, Mossberg's Investor Digest compiles all Best Idea Profiles generated that month into a single compilation issue.

Access to Past Compilation Issues – Password protected access to all previous compilation issues.

Immediate Access to Best Idea Profiles - Approximately two to three times per month, Immediate Access Annual Subscribers receive Best Idea Profiles as soon as they are published.

Annual Subscription: \$195/ year

12 Monthly Compilation Issues

Access to Past Compilation Issues

About Mossberg's Investor Digest

The value proposition of the digest is essentially an "Idea Generator". During the course of my 13-year career in capital markets, I've had the chance to meet and work closely with some very smart professional investors who have consistent track records of outperforming the market indexes. Some of these investors, which include mutual fund managers, hedge fund managers, and other professional investors, are kind enough to share their best ideas with me. I conduct my own analysis of their ideas and publish summaries of those ideas I think represent timely investment opportunities. Over time, I trust the majority of these ideas will pan out and help subscribers generate index-beating returns.

The goal of the Best Idea Profiles in this newsletter is to describe all of relevant investment merits and risks of a company in one page. It is not intended to be an exhaustive report including every detail of a company. With limited space available, I am forced to include only those data points that I feel are most important for subscribers to know before they begin their own due diligence. Thank you for your interest in Mossberg's Investor Digest.

Disclosures

Not Investment Advice: Investors should consult a financial advisor before investing in any securities highlighted in the Digest or subscribing to any newsletter service. We attempt to provide subscribers with reasoned opinions based on our analysis of publicly available information from sources believed to be reliable, but make no representations as to its accuracy or completeness. Best Idea Profiles highlighted in Mossberg's Investor Digest are not based upon individual needs of subscribers nor are they an offer to buy or sell securities. Mossberg's Investor Digest is not suitable for people seeking low to moderate risk investments.

It is the policy of the publisher to follow the CFA Institute's "Standards of Practice" regarding disclosure of potential conflicts of interest. The publisher's policy is to avoid conflicts of interest when possible. However, when potential conflicts are unavoidable, the publisher's policy is to disclose material business relationships between it and issuers of securities highlighted in the letter. In addition, the publisher's ownership in securities highlighted in the letter is disclosed. By disclosing potential conflicts of interest, subscribers and prospective subscribers will have additional information to evaluate the objectivity of ideas highlighted in the newsletter.

*There are no material business relationships between the publisher and the securities highlighted in this issue.

*The publisher owns shares in DELL, EPM, ISSI, NVAX, OPMR, VRTS, and WU.

We attempt to provide subscribers with reasoned opinions based on our analysis of publicly available information from sources believed to be reliable, but make no representations as to its accuracy or completeness. Best Idea profiles are not based upon individual needs of subscribers nor are they an offer to buy or sell securities. Additional disclosures can be found under the Disclosures portion of the Mossberg's Investor Digest website.

www.mossbergid.com